mens other than if an inferior control group [e.g., cyclosporine (CSA) and prednisone alone, which are not considered standard of care at most U.S. centers] or a composite end point (e.g., incidence of AR, graft loss, and death) is used. 6 In addition, the trials do not adequately assess the utility of these agents in high risk populations (e.g., African Americans, repeat transplants, and patients with high PRAs [panel reactive antibodies] or those with delayed graft function). Other limitations of some of the recent renal trials are that they have enrolled a large percentage of lower risk patients (e.g., living donors) and some have randomized patients after insuring good graft function. 4, 6 Immunosuppressive regimens vary from center to center and differ according to organ type. Based on the most recent UNOS (United Network for Organ Sharing) reports, TRL is the preferred agent in liver, pancreas, and kidney-pancreas transplantation, whereas CSA and TRL share the marketplace for initial therapy in kidney transplantation (TRL 49% and CSA 44%). CSA remains the predominant agent in heart transplantation whereas the number of lung transplant centers using primary TRL has recently increased to 44%. Newer combinations of agents (e.g., TRL and mycophenolate, TRL and SRL, mycophenolate and SRL) are under study to identify better combinations than are currently used. With the use of these more potent regimens has come the idea to use calcineurin-sparing regimens, steroid-minimization regimens, or possibly even complete steroid avoidance.
The use of induction therapy in other organs varies, and most of the clinical trials leading to Food and Drug Administration approval of the newer IL-2 receptor blocking agents have been compared to control therapy consisting of no induction. 6, 9, 10 Questions remain regarding the efficacy of polyclonals versus monoclonals and whether their use is actually necessary in all patients or just high risk patients (e.g, retransplants, high PRAs, or certain subpopulations such as African Americans). Studies are under way to address some of these issues.
None of these agents has been officially approved for lung transplantation, and in fact, very few have been studied in a randomized prospective manner in this population. [11] [12] [13] [14] Immunosuppression in lung transplantation has relied on extrapolating data from kidney, liver, and heart studies; however, one must recognize the limitations of phase III trials performed in other organs because none of these studies address the specific challenges faced in lung transplantation. The incidence of both AR and obliterative bronchiolitis remains high. Current actuarial survival rates at 1, 3, 5, and 7 years of 72, 58, 43, and 34%, respectively, clearly support the need for better immunosuppressive regimens in lung transplantation. 15 In addition, the high prevalence of obliterative bronchiolitis; in excess of 50% at 5 years, 16 and poor long-term survival, 20% at 9 years, further demonstrate the need for better immunotherapy. 17 
DRUG THERAPY
Triple drug regimens remain the cornerstone of most lung transplant protocols in use today. Current maintenance immunosuppressive regimens consist of combinations of immunosuppressive agents that are utilized for the lifetime of the patient, such as, calcineurininhibitor, CSA modified solution (Neoral or one of its generics) or TRL (Prograf ), an antiproliferative agent, MMF (Cellcept) or azathioprine (Imuran or its generic), and corticosteroids. SRL (Rapamune) has recently been introduced and, depending on circumstances, is being used to replace either the calcineurin inhibitor or the antiproliferative agents. Some centers use induction therapy with antilymphocyte-antibody therapy (e.g, Thymoglobulin, Atgam, or OKT3) or the new IL-2 receptor blocking agents (e.g., daclizumab, Zenapax or basiliximab, Simulect) as induction therapy.
Cyclosporine

BACKGROUND
Introduced in 1979, CSA markedly improved 1-year graft survival and rejection rates in kidney transplant recipients, which resulted in generalized acceptance among other organ transplants shortly thereafter. 18 The addition of CSA to the immunosuppressive regimens significantly changed the face of solid organ transplantation.
Food and percent fat content have been reported to have a greater effect on the Sandimmune as compared to the Neoral formulation. Consequently, Neoral has now largely replaced Sandimmune based on Neoral's improved bioavailability (30-45%), more consistent oral absorption, less variability in CSA pharmacokinetics, and lesser dependence on bile for absorption. 21 CSA is a highly lipophilic compound that is distributed extensively in the blood; ϳ58% is bound to red blood cells (RBCs) and ϳ33% in plasma bound primarily to lipoproteins (ϳ90%).
The cytochrome p4503A4, and to a lesser extent CYP3A5, enzymes are responsible for the metabolism of CSA. [22] [23] [24] Both of these enzymes are located in the liver and in the intestine. 22, 25, 26 Intestinal metabolism is partially responsible for the decreased bioavailability seen with CSA and the other immunosuppressants, TRL and SRL. 27, 28 Another factor that plays a significant role in the metabolism of all of these agents is P-glycoprotein (P-gp), which is a counter transport protein responsible for pumping drugs out of cells and back into the intestinal lumen. 29 This substance was originally associated with multidrug-resistant tumor cells and has been subsequently identified on the surface of normal cells located in the small and large intestine, bile ducts, and kidney proximal tubules. 30, 31 
THERAPEUTIC DRUG MONITORING
Drug level monitoring is performed routinely in all transplant patients maintained on CSA due to the intra-and interpatient variability seen with this drug. Controversy has existed throughout the years regarding the appropriate media (whole blood or plasma), the assay [high performance liquid chromatography (HPLC) or an immunoassay] and type of pharmacokinetic analysis [trough, total body exposure (pharmacokinetically referred to as Area Under the Curve or AUC), abbreviated AUCs with 1-3 levels, or, most recently, C2 monitoring of a "pseudopeak" concentration at 2 hours after the dose] 32-34 that should be to used to optimize CSA therapy. Most centers in the United States continue to perform trough-level monitoring because of the obvious ease of knowing when a patient is at the lowest concentration. The primary reason for attempting to identify alternative pharmacokinetic monitoring strategies has been related to the poor correlation with trough concentrations, AUC, and outcome for CSA. 35, 36 
DRUG INTERACTIONS
Drug interactions occur commonly with CSA and require very close monitoring. 37, 38 CSA is metabolized by the CYP3A4 system in both the gut and the liver, which accounts for both its poor bioavailability and numerous drug interactions. 22, 25, 26 CSA is also a substrate for P-gp, a countertransport protein responsible for pumping CSA back into the gut lumen and decreasing its absorption. 29 The influence of both CYP3A4 and P-gp contribute greatly to CSA's absorption and propensity to interact with other drugs known to act at those sites.
Drugs or other substances capable of inducing CYP3A4 and P-gp (e.g., rifampin, phenytoin, St. John's wort) [39] [40] [41] cause a decrease in CSA's concentration, whereas those that inhibit or compete for metabolism (e.g., ketoconazole and other azole antifungals, 42 macrolide antibiotics such as erythromycin, clarithromycin, 43, 44 and the calcium channel blockers, diltiazem, [45] [46] [47] verapamil, [48] [49] [50] nicardipine, grapefruit juice, etc.) will increase its concentration (Table 1) . [41] [42] [43] [44] 51 Drug interactions have been used intentionally in lung transplantation (e.g., administration of erythromycin) to improve the absorption of CSA and in other transplant populations (e.g., ketoconazole, diltiazem) to reduce the overall cost of therapy. Intentionally induced interactions need to be monitored closely because dosage adjustments (e.g., increases or decreases), changes or discontinuation of interacting agent, and compliance with the interacting agent all determine the magnitude of the interaction. Simple changes from one agent to another (e.g., ketoconazole to fluconazole, diltiazem to nifedipine), could result in subtherapeutic levels and predispose the patient to AR. Similarly, the addition of potent enzyme inhibitors (e.g. ketoconazole, erthromycin) can cause two-to fivefold increases in CSA concentration resulting in profound toxicity unless the CSA dosage is decreased.
DOSING
Much higher doses of CSA (e.g., 15-25 mg/kg) were used initially when CSA was first introduced; however, because of the concentration related side effects, total daily dosages have decreased as centers have gained more experience. Initial doses of CSA typically range in the 8 to 10mg/kg/day and are adjusted to achieve specific blood concentrations (e.g., 200-300 ng/mL). Patients with cystic fibrosis or those with poor absorption may require higher dosages. Target levels are based on the patient's background immunosuppression, the time interval following transplantation (e.g., higher levels used immediately after transplantation as compared with 12 months or 2 years following transplantation), and the clinical course (e.g., patients with more frequent rejection episodes are usually maintained on higher concentrations whereas those exhibiting signs of toxicity may have their drug concentrations decreased).
Several oral formulations of CSA are available commercially. The first formulation of CSA introduced onto the market was Sandimmune, which was followed by the Neoral modified solution. These two formulations exhibit distinct pharmacokinetic profiles, and it is important to recognize that Sandimmune is not bioequivalent to Neoral or any of Neoral's AB-rated generic equivalents. 52 Generic formulations of Neoral have been available since 1999, and there are currently three AB- 
ADVERSE EFFECTS
CSA has numerous unwanted side effects, most of which result from calcineurin inhibition. 18 The most serious adverse drug effects include renal dysfunction (decreased GFR, hyperkalemia, hypomagnesemia), hypertension, hyperlipidemia, gout, osteoporosis, posttransplant diabetes, and cholelithiasis. [53] [54] [55] [56] [57] [58] [59] [60] Other side effects include neurotoxicity (e.g., tremors, peripheral neuropathy), gingival hyperplasia, and hirsutism.
Tacrolimus BACKGROUND
TRL (formerly FK506) was approved in 1994 and has been used as an alternative agent for CSA in double and triple drug regimens. 61 
CHEMISTRY
TRL, a macrolide antibiotic compound derived from Streptomyces tsukubaensis, shares a similar mechanism of action to that of CSA, but TRL is 10 to 100 times more potent. 62 TRL binds specifically to FK binding protein (FKBP), a cytoplasmic immunophillin, resulting in calcineurin inhibition and ultimately inhibition of IL-2. To a lesser extent than CSA, TRL induces transforming growth factor (TGF-␤1), which possesses potent immunosuppressive activity and fibrogenic potential that are thought to contribute to immunosuppressive and nephrotoxic properties of these agents. [63] [64] [65] TRL appears to undergo demethylation or hydroxylation, resulting in at least nine metabolites. [66] [67] [68] 
PHARMACOKINETICS
Similar to CSA, oral TRL is incompletely absorbed (e.g., oral bioavailability of TRL is ϳ20-25%) but absorption is independent of bile. 69 The poor oral bioavailability is most likely due to the fact that TRL is also subject to inter/intrapatient bioavailability alterations mediated by P-gp and metabolic enzymes (CYP3A4) in the gut. 62 A fatty meal (46% fat) has been reported to reduce both the rate and the extent of absorption by up to 37% for TRL. Because of this food effect, it is recommended that patients be consistent with how they take their TRL. To completely avoid any food effect, TRL should be taken 1 hour before or 2 hours after a meal. 70 TRL is also widely distributed in the blood, ϳ75 to 80% bound to erythrocytes, thus whole blood concentrations can be expected to be 15 to 30 times greater than measured in plasma. The half-life of TRL is ϳ12 hours in liver transplant recipients and ϳ19 hours in kidney transplant recipients. 62 Both agents are primarily excreted in the bile and have minimal renal elimination. 71 Consequently, drug dosage modifications are not necessary with hemodialysis or renal dysfunction.
THERAPEUTIC DRUG MONITORING
Trough concentrations are used routinely to assess efficacy and toxicity with TRL. A reasonably good correlation (r = 0.93-0.99) exists between trough concentrations and total body exposure (i.e., AUC) for TRL. [72] [73] [74] [75] [76] This relationship makes trough concentration monitoring a useful tool for TRL. In contrast, because of the relatively poor correlation reported between CSA AUC and trough concentrations, a number of investigators have suggested using abbreviated AUC or C 2 or C 3 concentration monitoring. [32] [33] [34] [35] [36] Drug concentrations need to be monitored whenever the patient's condition changes, toxicity is suspected, or other drugs metabolized by CYP4503A are administered concomitantly or discontinued.
DRUG INTERACTIONS
Like CSA, TRL is also susceptible to many pharmacokinetic or pharmacodynamic clinically significant drug interactions associated with their metabolism through the cytochrome p450 3A4 isoenzyme system and P-gp. 37, 38 Therefore, as additional drugs are added or discontinued from the patient's drug regimen, drug concentrations should be monitored if the agents have the potential to interact. Inhibitors include amiodarone, clarithromycin, erythromycin, diltiazem, nicardipine, verapamil, fluconazole, itraconazole, ketoconazole, and grapefruit juice. [77] [78] [79] Inducers include carbamazepine, phenobarbital, phenytoin, rifampin, and St. John's Wort. 78, 80 New agents should also be evaluated for their potential additive side effects such as nephrotoxicity, neurotoxicity, hepatoxicity, hyperlipidemia, and hyperglycemia as well as their effects on the metabolism of CSA, TRL, and SRL.
Until recently, it has been assumed that agents known to interact with CSA will also interact with TRL; however, there are at least three exceptions to this generalization. There is not an interaction between TRL and the HMG-CoA (hydroxymethylglutarylCoA) reductase inhibitors (e.g., lovastatin, simvastatin, fluvastatin, etc.) nor between MMF and TRL (described in greater detail below). [81] [82] [83] There also does not appear to be an interaction between SRL and TRL as there is between CSA and SRL. However, a preliminary report suggests that TRL concentrations may be decreased slightly in the presence of SRL. 84 
DOSING
The usual starting dosage for transplant patients of TRL is 0.1 to 0.2 mg/kg/d administered orally as a twice-daily dosage or 0.025 to 0.05 mg/kg/d as a continuous intravenous infusion. The dosage of 0.3 mg/kg/day used for liver patients is usually too high for thoracic patients. Initially, TRL concentrations are titrated to achieve whole-blood levels of 10 to 20 ng/mL or plasma levels of 0.5 to 2 ng/mL; lower concentrations (5 to 10 ng/mL) are used after 6 months if there are no rejection episodes.
Both TRL and CSA are subject to pharmacokinetic variability; thus pediatric and African American patients may require increased dosages; elderly patients or those with liver dysfunction may require longer intervals of administration. 18, 85 
ADVERSE EFFECTS
CSA and TRL exhibit similar side effects, however the incidence varies between the two agents. Nephrotoxicity, neurotoxicity, electrolyte imbalances, headaches, bruising, hepatotoxicity, infection, nausea, vomiting, and diarrhea seem to occur to a similar degree among patients treated with TRL or CSA. 86, 87 Hyperlipidemia, hypertension, and increased uric acid or gout occur more frequently with CSA. However, CSA is associated with several unique side effects including acne, hirsutism, gingival hyperplasia, increased appetite, and pancreatitis. Alopecia, hyperglycemia, and mental status changes have been reported more frequently with TRL. In a recent renal study targeting lower TRL concentrations, the incidence of posttransplant diabetes in patients receiving TRL and mycophenolate was identical to that of CSA and mycophenolate, suggesting that other factors (e.g., steroid usage) may play a more significant role. 88, 89 TRL has also been used as a "rescue" agent in patients with recalcitrant rejection. 90 Many of these side effects are dose and serum concentration dependent and also affected by other immunosuppressive agents the patient is receiving.
CLINICAL STUDIES
The majority of experience with TRL in cardiac transplant recipients comes from four trials, one nonrandomized and three randomized trials comparing TRL-and CSA-based protocols. 87, 89, 91, 92 The overall incidence of rejection during the first year appears similar to that with CSA; however, the incidence of side effects such as hyperlipidemia and hypertension occur less frequently with TRL.
There have been two randomized, open-label, controlled trials of TRL in lung transplant recipients. Keenan et al randomized 133 single or bilateral lung recipients to either CSA-or TRL-based regimens. The 1-year and 2-year patient survival rates were not significantly different between the two groups; however, there was a trend to improved survival at 2 years in the TRL group. AR episodes were fewer in the TRL group, 0.85 rejection episodes/100 patient days as compared with 1.09 for CSA. Of note, fewer patients in the TRL group developed OB (obliterative bronchiolitis) (21.7%) compared with CSA (35.8%) p = 0.025. 13 The major limitation of this study is that there has not been further follow-up to determine whether the trend for better survival continued beyond 2 years and whether the lower incidence of OB was maintained. The second study was published recently and evaluated a total of 50 patients randomized to either TRL or CSA in combination with MMF and prednisone. 14 There was no difference in 6-and 12-month survival; however, it is also unlikely that it was adequately powered to detect major differences in survival. Freedom from AR at 6 months and 1 year was slightly higher in the TRL group (57.7 and 50% vs 45.8 and 33.3%) but not statistically significant. Similar to the Keenan study that used azathioprine (AZA) as its antiproliferative agent, there were less treated rejection episodes per 100 patient days (TRL 0.225 vs CSA 0.426, p < 0.05), but the absolute number appears lower in both arms treated with MMF. To further confound the analysis of these data, four patients in the CSA group were switched to TRL and two patients in the CSA group were retransplanted. This study is limited by the small number of patients and the short follow-up but suggests improved efficacy with TRL and MMF.
TRL has been used to treat recurrent or persistent AR. In a retrospective analysis of 14 patients, both the incidence and the severity of AR declined significantly after maintenance immunosuppressive treatment was changed from CSA to TRL. 93 TRL has also been used to treat OB in a number of nonrandomized trials in which pulmonary function appeared to have stabilized after switching therapy. 94, 95 Most of these trials are limited by the small number of patients, nonstandardized definitions of stabilization, short-term follow-up, and the variable nature of OB.
Azathioprine BACKGROUND
AZA is a pro-drug that is an imidazole derivative of the antimetabolite 6-mercaptopurine (6-MP). It has played an important role in double (e.g., conventional immunosuppression) and triple drug therapy transplant regimens throughout the years. In kidney, liver, and heart transplantation, it has largely been replaced by newer immunosuppressive therapies, including MMF or SRL.
CHEMISTRY
AZA is a pro-drug that is rapidly converted in the liver and RBCs into 6-MP, which is then incorporated into cellular deoxyribonucleic acid (DNA) whereby it in-hibits purine nucleotide synthesis. 96 It interferes with metabolism of ribonucleic acid (RNA) effectively inhibiting gene replication and subsequent T-cell activation. Because AZA does not affect gene activation, it is not effective for treating rejection.
This pro-drug is rapidly hydrolyzed in vivo to 6 mercaptopurine, which then undergoes metabolism by three pathways, including degradation to thiouric acid, conversion to thiopurine nucleotides, and methylation of the thiol group. [97] [98] [99] [100] Xanthine oxidase is responsible for the metabolism of 6-MP to thiouric acid, which is a major pathway for detoxification of this agent. Hypothanthine guanine phosphoribosyltransferase metabolizes 6-MP to the thiopurine nucleotides of which thioinosinic acid is an inhibitor of purine synthesis. The 6-TGNs incorporate into DNA and probably are toxic to dividing cells. Thiopurine methyltransferase is responsible for thiomethylation of 6-MP. 101 This latter enzymatic process is controlled by a common genetic polymorphism with 1 in 300 subjects being homozygous for low activity, 11% having intermediate activity, and 89% high enzymatic activity. The clinical significance of this genetic polymorphism is not well understood; however, it may be responsible for some patients requiring very low doses of AZA. 102, 103 
PHARMACOKINETICS
AZA exhibits rapid and incomplete oral absorption with a bioavailability of ϳ40%. Although both AZA and 6-MP have relatively short half-lives-12.5 ± 3.0 minutes and 50.4 ± 36.6 minutes, respectively, the halflife of RBC thioguanine nucleotides appears to be quite long (e.g., 13 days), 100 which allows for once daily dosing.
DRUG INTERACTIONS
The most significant and potentially life-threatening drug interaction that can occur in transplant patients treated with AZA is with allopurinol. Hyperuricemia and gout are relatively frequent complications following transplantation, especially in patients treated with CSA. Allopurinol is often used to treat hyperuricemia; however, because it is a xanthine oxidase inhibitor, it blocks the metabolism of 6-MP, which results in increased bioavailability and a fourfold increase in 6-MP concentrations. If this interaction is not recognized, profound pancytopenia and death can occur. 104, 105 The addition of allopurinol to a regimen containing AZA requires an initial dose reduction of 75 to 80% for AZA followed by increased monitoring of complete blood counts with platelets for approximately 4 to 8 weeks. 106 Many practitioners would preferentially switch the patient to MMF because it does not interact with allopurinol. If the hyperuricemia is primarily related to CSA administration, a better option is to switch the patient to TRL, which does not cause hyperuricemia. This maneuver minimizes the complication rather than adding an additional medication to treat the CSA-induced hyperuricemia.
Other clinically important interactions may occur with the concomitant administration of bone marrow suppressive agents (e.g., ganciclovir, trimethoprimsulfamethoxazole, SRL), and gastrointestinal irritants (e.g., nonsteroidal antiinflammatory agents, prednisone).
DOSING
Depending on the organ type, an initial dose of 3 to 5 mg/kg per day of AZA can be administered preoperatively. Immediately after transplantation, a maintenance dose of 1 to 3 mg/kg per day is titrated to patient tolerance as determined by a desired WBC (white blood count) in the range of 3,500 to 6,000 cells/mm 3 . WBC counts less than 3,000 cells/mm 3 usually necessitate temporary discontinuation of the drug and/or subsequent dosage reduction (e.g., 25 mg/day). Because the half-life of RBC TGN is so long (e.g., 13 days), oncedaily dosing of AZA is adequate. Therapeutic drug monitoring of AZA is not performed routinely; however, the level of TGN in the tissues may be the more clinically relevant level to be measured. 96 Based on the reduced bioavailability of AZA, it has been suggested that the dose of AZA be reduced by 50% when converting from the oral to the intravenous route of administration. 96 Due to its complex metabolic pathway, it is not clear whether adjusting the dosage of the pro-drug (i.e., AZA) is necessary because the immunologic activity is actually conveyed by its metabolites. The practical approach is to evaluate the complete blood count (CBC) when intravenous therapy is indicated, and if it is already decreased, a reduced dose of AZA (e.g., 50%) should be administered intravenously.
The clearance of AZA is not affected by renal impairment; however, more important, its metabolite 6-thioguanine may accumulate with renal impairment contributing to enhanced toxicity. Dosing guidelines for renal impairment are not available.
ADVERSE EFFECTS
AZA is a broad-acting myelosuppressive agent. The primary toxicity of this agent is dose-related bone marrow suppression manifested as leukopenia, thrombocytopenia, or macrocytic anemia. This usually appears 7 to 14 days after initiation of the agent. 107 Dosage adjustments or discontinuation of the agent should be based according to monitored CBCs with platelets. AZA may cause gastrointestinal side effects including diarrhea, hepatitis, or cholestasis that would be reflected in abnormal liver function tests including bilirubin or transaminase. Alopecia is also more common with AZA and is partially responsible for the alopecia reported in the initial TRL, AZA, and prednisone regimens. 108, 109 Mycophenolate Mofetil BACKGROUND Mycophenolic acid (MPA) was initially developed in the 1960s as a potential antibiotic, antineoplastic, and antipsoriatic agent. It was not until years later that it was resurrected as a potential immunosuppressive agent for organ transplantation. Due to problems with absorption of the parent compound, an ester derivative of MPA was developed to improve its absorption profile and it is the pro-drug formulation that is currently in use.
CHEMISTRY
MMF is a pro-drug that is rapidly hydrolyzed to the active ingredient mycophenolic acid, which is an anti-T and -B cell agent that has less bone marrow toxicity than AZA. 110, 111 MPA inhibits T-cell proliferation by competitively and reversibly inhibiting inosine monophosphate dehydrogenase (IMPDH), resulting in the blockade of de novo synthesis of guanosine nucleotides, which are necessary substrates of DNA and RNA synthesis. 111 Because T and B lymphocytes are reliant upon de novo pathway for synthesis of guanosine, their proliferation is selectively inhibited as compared with other cell types, which can use the salvage pathway. 110 This selectivity results in less bone marrow suppression than with nonselective agents such as AZA.
PHARMACOKINETICS
Following oral administration, MMF is rapidly absorbed and hydrolyzed to its active form MPA in the liver and then glucuronidated to its inactive metabolite mycophenolic acid glucuronide (MPAG). Compared with patients immediately posttransplant, MPA peak plasma concentrations are ϳ50% higher in stable renal transplant recipients (> than 3 months posttransplant). 111 MPA is eliminated primarily in the urine as MPAG; however, enterohepatic recirculation of the inactive metabolite MPAG may occur. CSA may interfere with this process, resulting in lower MPA and MPAG concentrations associated with CSA therapy as compared with TRL. 81, 83, 112 Additionally, MPAG accumulation and reconversion via beta-glucuronidation to MPA may occur in patients with renal dysfunction. These mechanisms could possibly contribute to overimmunosuppression or toxicity. 111 Although current guidelines do not exist, doses exceeding a total daily dose of 2 g are not recommended in patients with renal dysfunction.
THERAPEUTIC DRUG MONITORING
Therapeutic drug monitoring is not performed routinely with MMF, however, because MPA is primarily eliminated by the kidneys and it is also highly protein bound to albumin, monitoring may prove useful in optimizing efficacy and/or minimizing toxicity. Some investigators have suggested that levels correlate with clinical efficacy and have found it necessary to administer doses as high as 6 g/day to achieve therapeutic levels. Drug concentration monitoring may also be useful if concerns exist regarding potential drug interactions, as described in the following text. 113, 114 
DRUG INTERACTIONS
No metabolic drug interactions have been reported with MMF. However, impaired absorption by 37 to 40% has been reported with the concomitant administration of antacids or cholestyramine. 115 A preliminary report in normal healthy volunteers showed a 90% reduction in MPA levels with a single-dose administration of ferrous sulfate. 116 This interaction may be due to chelation similar to that seen with aluminum-and magnesiumcontaining antacids.
Decreased MPA trough concentrations have been reported when MMF is administered with CSA compared to those achieved with similar MMF doses in patients receiving TRL or SRL. [81] [82] [83] 112 This interaction was originally thought to be caused by a drug interaction with TRL causing increased MPA levels, 117 but instead is due to CSA interfering with the enterohepatic recycling of the MPAG, resulting in decreased MPA concentrations. 83 To achieve MPA and MPAG concentrations equivalent to those seen with MMF 2.0 g/day and concomitant TRL, it may be necessary to administer doses of MMF 3.0 g/day with CSA. Antibiotics may also interfere with the enterohepatic recirculation of MPAG and reabsorption of MPA, resulting in lower MPA concentrations.
Increased acyclovir and MPA's glucuronide metabolite concentrations have been reported secondary to competition for renal tubular secretion. 110 MPAG elimination may be competitively inhibited by other agents that undergo renal tubular secretion, including probenecid or ganciclovir, even though this was not observed in a single dose study with ganciclovir. 118 Because both MPA and MPAG are highly protein bound to albumin, ϳ99% and 82%, respectively, it is possible that competition for binding sites may occur with other highly protein-bound drugs (e.g., phenytoin, high-dose aspirin) or that binding may be altered with concomitant disease states such as uremia, hyperbilirubinemia, or hypoalbuminemia. 119 
ADVERSE EFFECTS
MMF generally is a well-tolerated agent; however, side effects are more frequent with increased dosages (> 3 g/day). 1 Side effects can include abdominal pain, nausea, dyspepsia, gastroenteritis, vomiting, bone marrow suppression (thrombocytopenia, anemia, leukopenia, pancytopenia), and opportunistic infections. Gastrointestinal side effects can be decreased by admin-istering the dose with a small amount of food or by splitting the day's total regimen into four rather than two doses. If the side effects do not subside, then a reduction in total daily dosage should be considered.
CLINICAL STUDIES
MMF was approved for use in renal transplant patients in 1995, heart transplant patients in 1998, and liver transplant patients in 2000 as an alternative to AZA. Three pivotal multicenter clinical trials in kidney transplant recipients demonstrated improved efficacy with MMF compared with AZA-based regimens. AR rates were reduced significantly from over 40% in the control arm to 20 to 25% with MMF therapy. [1] [2] [3] 120 Based on these studies, MMF has largely replaced AZA at most renal transplant centers because of its improved efficacy and minimal effects on other organ systems.
MMF has demonstrated efficacy both as maintenance immunosuppression and as "rescue" therapy for rejection episodes for heart transplant patients. [121] [122] [123] An international, multicenter, randomized, blinded 3-year comparison of MMF (3 g/d) and AZA (1.5 to 3.0 mg/kg/d) in combination with CSA and oral corticosteroids recently completed enrollment of 650 primary heart transplant recipients. 124 In treated patients (MMF, n = 289; AZA, n = 289), the MMF group compared with the AZA group was associated with significant reduction in mortality at 1 year (6.2% vs 11.4%; p = 0.031) and a significant reduction in the requirement for rejection treatment (65.7% vs 73.7%; p = 0.026). Opportunistic infections, mostly herpes simplex, were more common in the MMF group (53.3% vs 43.6%; P = 0.025). A recent analysis of 5599 patients in the joint International Society for Heart and Lung Transplantation (ISHLT) and UNOS Thoracic Registry showed an actuarial survival advantage for MMF when comparing MMF with AZA (1 year, 96% vs 93%; 3 years, 91% vs 86%, p = 0.0012). 125 This study focused on patients who were discharged from the hospital, whereas the original MMF trial was an intent-to-treat analysis, which included all patients randomized prior to transplantation, some of whom never received a dose of study medication.
A prospective, randomized, open-label international MMF lung trial, evaluating the primary end point of bronchiolitis obliterans syndrome (BOS) incidence at 3 years, is currently under way in 320 recipients. Preliminary 12-month data showed no significant difference in AR 51.3% versus 50.9% or in the incidence of BOS 3.8 versus 3.1% with AZA compared with the MMF groups, respectively. Patients received either MMF 3 g/day for 3 months followed by 2 g/day or AZA 2 mg/kg/day in conjunction with CSA, prednisone, and up to 10 days of antithymocyte therapy. However, improved survival was evident in the MMF group 88.1% versus 79.1% in the AZA treated patients (p = 0.03). 12 More patients in the AZA arm discontinued therapy by one year, 40.7% compared with 26.5% in the MMF group. Primary reasons for withdrawal from therapy included adverse drug reactions, death, and poor response.
A number of single center trials have reported favorable results with MMF therapy in a limited number of lung transplant recipients. This has included a lower incidence of AR, [126] [127] [128] efficacy for AR rescue therapy, 129, 130 and a benefit for the treatment of OB. 131 In the largest of these trials, Zuckermann et al compared MMF with AZA in 38 lung transplant recipients and found the incidence of histologically proven AR in the group treated with MMF to be significantly lower 6 months after transplant (24% vs 87% ). 132 The survival rate at 6 months was 76% in the group treated with MMF and 65% in the AZA-treated group. Mean number of rejections was 0.29 ± 0.10 with MMF versus 1.53 ± 0.29 in the AZA arm (p < 0.01). After 6 months the freedom from any rejection was higher in the MMF group-73% versus 12% in the AZA group, (p < 0.05). The lower incidence of AR reported in this trial is more impressive than that reported in the MMF multicenter lung trial; however, survival rates were lower in this study.
Prednisone
BACKGROUND
Originally used in the 1960s, corticosteroids remain a consistent and controversial component of modern-day immunosuppressive strategies. Despite long-standing experience with these agents, clinicians continue to debate the appropriate utilization or absence of corticosteroids in the continuum of immunotherapy. 133 
CHEMISTRY
Corticosteroids are nonspecific anti-inflammatory agents that inhibit both humoral and cell-mediated immunity. Corticosteroids exert their immunosuppressive effects by several mechanisms: inhibition of macrophage and T-cell cytokine production including IL-2, tumor necrosis factor, interferon-gamma; inhibition of IL-1, IL-2, and IL-6 synthesis. As a result, T-cell activation is blocked. Given their nonselective immunosuppressive properties, implementation of corticosteroids has been successful in many facets of solid organ transplantation, including prevention and treatment of rejection.
DRUG INTERACTIONS
Corticosteroids are metabolized via the cytochrome p450 enzyme system. Agents that induce or inhibit this system may alter plasma concentrations of prednisolone, the circulating immunosuppressive active metabolite of prednisone and methylprednisolone. Corticosteroid dosage modifications may be empirically considered, especially if used in concert with potent in-teracting agents including rifampin, phenytoin, phenobarbital, or ketoconazole. Dosage adjustments are generally not required with hepatic or renal dysfunction. When either prednisone or prednisolone is administered, only a small amount is excreted unchanged in the urine as prednisone (2-5%) or prednisolone (7-24%).
DOSING
Prednisone and methylprednisolone are the most commonly prescribed corticosteroids in transplant recipients. Both of these agents are metabolized into the active metabolite prednisolone. Despite a relatively short half-life (2 hours), the pharmacological activity demonstrated by inhibition of lymphokines persists for 24 hours; thus once-daily dosing is adequate. Corticosteroids are used in a variety of different ways in the transplant setting: high dose, typically consisting of short courses of intravenous methylprednisolone (250-1000 mg) for 3 days or oral pulse doses in cases of mild AR. Maintenance regimens are gradually tapered over an appropriate period of time to a standard low dose.
ADVERSE EFFECTS
The side effects of corticosteroids are well known and include hypertension, hyperlipidemia, neurotoxicity, diabetes, osteoporosis, growth retardation, acne, and gastrointestinal toxicity. The majority of these side effects are dose dependent and/or duration dependent. Studies analyzing bone loss after transplantation consistently report that it is most significant within the first year following transplantation, and most of it occurs within the first few months. 134, 135 CSA and TRL may also contribute to the bone disease seen following transplantation. 136 Lung transplant patients may be particularly prone to the development of bone disease because of their long-standing disease, immobility, and pretransplant steroid usage.
Sirolimus BACKGROUND
SRL was approved in 1999 for renal transplantation and is the newest immunosuppressive agent to be added to the immunosuppressive armamentarium. The safety and efficacy of SRL in the prevention of organ rejection have been demonstrated in two randomized, doubleblind, multicenter controlled trials involving 1295 renal transplant patients. An analog of SRL, SDZ-RAD, is manufactured by Novartis and is currently being studied in phase III clinical trials in kidney, liver, heart, lung, and pediatrics.
CHEMISTRY
SRL was isolated from Streptomyces hygroscopius and was originally studied for potential antifungal properties. It is a macrolide structurally related to TRL, but SRL exhibits a novel mechanism of action and distinct sideeffect profile. Like TRL it elicits its activity by binding to immunophilins, forming the SRL-FKBP complex. In contrast to CSA and TRL, SRL does not inhibit calcineurin but rather inhibits the activity of the mammalian target of rapamycin (mTOR), a kinase enzyme. Inhibition of mTOR blocks cytokine-mediated cell proliferation between phase G1 and S and ultimately inhibits T-and B-cell proliferation. 137 Given that TRL and SRL bind to the same FKBP, there were concerns that the two agents should not be administered together because they might either compete or antagonize each other. Subsequent studies have demonstrated that this binding protein is ubiquitously available in vivo; thus competition for the receptor is unlikely, and the two agents can be used together.
PHARMACOKINETICS
SRL is similar to CSA and TRL in that it exhibits great intra-and interpatient variability in its pharmacokinetics. 138 SRL is poorly absorbed following oral administration and has a bioavailability of ϳ15%. 139 The poor absorption is related to the fact that SRL is a substrate for P-gp, a counter transport efflux pump and is also affected by CYP3A4 in the gut.
SRL is highly lipophilic and is ϳ95% bound to RBCs. It exhibits a long half-life, approximately 57 to 62 hours, allowing for once-daily dosing 139 ; however, this has been reported to be shorter in children (11-12 hours) .
It undergoes metabolism into multiple metabolites in the small intestine and liver, mediated by the cytochrome p4503A enzyme system. Like calcineurin inhibitors, SRL is also substrate for P-gp, a counter transport efflux pump that is found in the gut.
SRL is eliminated ϳ2% in the urine with the remaining ϳ91% eliminated in feces. Dosage adjustments are unnecessary in renal dysfunction. It is unlikely that hemodialysis will remove SRL given its high lipophilicity and large volume of distribution. Dosage adjustments are required when hepatic dysfunction is present. Patients with mild to moderate hepatic dysfunction should be administered one-third the recommended dose. 140 
TDM
Because of the intra-and interpatient pharmacokinetic variability of SRL and the potential for drug interactions, it is necessary to perform therapeutic drug monitoring. The therapeutic levels for SRL are typically in the range of 10 to 20 ng/mL when it is used in combination with either TRL or CSA. Higher levels have been used in calcineurin-free regimens with MMF. 141 Assays are not currently available in all institutions and delayed turn around time may limit their utility for making therapeutic decisions. Because of the prolonged t 1 ⁄2 of SRL, it is not necessary to perform daily monitoring, and if levels are extremely low, it may be necessary to reload the patient to achieve steady state in a timely manner.
DRUG INTERACTIONS
Drug interactions that have been reported with CSA and TRL should be suspected with SRL. Clinically significant drug interactions will probably occur with any agent metabolized through the cytochrome p450 3A4 isoenzyme system. 38 Inhibitors or inducers of CYP450 3A4 isoenzyme system should be added cautiously to the transplant patient's regimen. Inhibitors include erythromycin, diltiazem, ketoconazole, fluconazole, and itraconazole among others. Inducers include but are not limited to phenytoin and rifampin. The potential magnitude of these interactions is clearly demonstrated by SRL's interaction with rifampin and ketoconazole; rifampin reduced SRL concentrations by 92%; after multiple doses of ketoconazole and SRL, a 990% increase in SRL level was observed. 137 Another important interaction occurs between SRL and CSA. This interaction demonstrates the importance of whether two drugs are administered at the same time or separately. A very significant interaction exists when the CSA and SRL are administered concomitantly (230% increase in SRL AUC) versus when the two medications are separated by 4 hours (80% increase in SRL AUC ). 142 SRL appears to be more vulnerable to this interaction; however, the clearance of CSA is also decreased but to a lesser degree (11-14%) at an SRL dose of 2 mg/day. This interaction is most likely dose dependent and the magnitude is affected not only by the timing of administration but the size of the dose, and as doses of either agent are adjusted corresponding changes in the other agent may be necessary. Because of this interaction and the possible risk of enhanced nephrotoxicity, it has been suggested at a minimum to monitor drug concentrations of both agents and to reduce the dosage of CSA. Current recommendations are to separate the administration of these two medications, but advocates of minimizing costly therapy may recognize that taking advantage of the drug interaction results in lower dosages of both drugs being administered. These cost savings must be balanced against the risk of nephrotoxicity and more frequent drug concentration monitoring of two agents.
Even though there are metabolic similarities with CSA, TRL, and SRL it is important to recognize that although SRL and CSA interact quite significantly, SRL and TRL do not interact in a similar manner. In fact, a recent report suggests that TRL levels may be decreased slightly during concomitant SRL administration at the 2 mg dose as compared with 1 mg/day. 84 These data support the premise that the interaction is most likely dose dependent; data are pending regarding the use of SRL at the 5 mg dosage level in combination with TRL. Because there is not a significant effect of TRL on SRL, it is likely that higher doses of SRL (12-15 mg loading dose followed by 5mg/day) will be necessary to achieve therapeutic levels. But as with all of these agents, drug concentration monitoring should be performed routinely.
ADVERSE EFFECTS
The side-effect profile of SRL is somewhat unique in that it has some side effects that are similar to CSA and yet it causes bone marrow suppression.
In the recent renal trials, a higher frequency of adverse effects was observed with SRL as compared with the control groups treated with CSA and prednisone; these included hyperlipidemia (including hypertriglyceridemia and hypercholesterolemia), hypertension, and rash. The hyperlipidemia should be managed appropriately utilizing exercise, diet modifications, and/or drug treatment with HMG-CoA reductase inhibitors. Clinicians should monitor patients closely when using HMG-CoA reductase inhibitors with SRL because they are metabolized through the same pathway in the liver (CYP4503A), and the possibility for competitive metabolism exists. These patients may be at an increased risk for myopathy or rhabodomyolysis, similar to that seen with CSA and the HMG-CoA reductase inhibitors.
Other side effects include bone marrow suppression (e.g., thrombocytopenia, anemia) as well as elevated liver function tests. Some of these side effects can be ameliorated with dosage alterations. 137 SRL does not cause nephrotoxicity by itself but appears to potentiate CSA's nephrotoxicity when the two agents are administered concomitantly. Current recommendations are to closely monitor levels of both agents and use reduced dosage as needed.
One relatively new side effect that has been reported primarily in renal transplant recipients is the development of an interstitial pneumonitis. 143, 144 The FDA has received reports of 34 cases of interstitial pneumonitis (also described as bronchiolitis obliterans, interstitial pneumonopathy, or pulmonary alveolar proteinosis) that were temporally associated with SRL therapy. 145 This side effect has not yet been reported in lung transplant recipients but needs to be included in the differential diagnosis in patients on SRL therapy who develop pulmonary manifestations.
CLINICAL STUDIES
The pivotal studies that led to the approval of SRL were all performed in conjunction with CSA and prednisone. Because of some of the toxicities seen with these regimens, including enhanced nephrotoxicity and hyperlipidemia, alternative regimens including TRL and SRL or calcineurin-sparing regimens such as MMF and SRL are currently being studied. 141, 146 . In Europe, SRL is approved for use in regimens that require the discontinuation of CSA within 3 months of transplantation.
Limited information is available currently on the use of SRL in lung transplant patients. A multicenter phase I trial was recently performed to examine the pharmacokinetics, safety, and tolerability of SDZ-RAD in patients with and without cystic fibrosis. 147 In a double blind randomized crossover study, 20 clinically stable lung and heart-lung transplant patients received single fasting oral doses of RAD at two dosage levels, 0.03 mg/kg (max 2.5 mg) and 0.10 mg/kg (max 7.5 mg), in addition to their maintenance therapy with Neoral, AZA, and corticosteroids. At both dose levels CF patients had slightly lower dose-normalized C max compared with non-CF patients (p = 0.05). Nonetheless, overall exposure (AUC) was not different between CF and non-CF patients (p = 0.60) at either dosage level. RAD disposition in these patients was similar to that previously characterized in stable renal transplant patients. Overall systemic exposure to RAD was similar in CF and non-CF lung transplant patients. Singledose RAD did not affect the pharmacokinetics of CSAmodfied solution, but this interaction will most likely be more apparent during multiple-dose administration.
It has been shown in animal airway transplant models that administration of rapamycin (SRL) markedly inhibits the fibroproliferative response to transplantation. Because OB probably represents the result of this response to injury, it is possible that the use of rapamycin in lung transplant will lessen the impact of this devastating complication. 148, 149 A study is under way comparing the efficacy of oral doses of rapamycin derivative, RAD (1.5 mg b.i.d.) with AZA (1.0-3.0 mg/kg/ day) in stable lung or heart-lung transplant recipients at risk for developing BOS as measured by the decline in FEV 1 at 12 months. The goal is to enroll 230 patients and also assess the cumulative incidence of BOS and the rate of decline in PFTs, and the cumulative incidence of AR out to 3 years after initiating therapy.
POLYCLONAL/MONOCLONAL AGENTS
In addition to maintenance therapy, a number of centers use either monoclonal or polyclonal induction agents, including OKT3, the antithymocyte globulins (e.g., Thymoglobulin and Atgam), or the IL-2 receptor blockers (e.g., daclizumab, basixlimab) ( Table 2 ).
OKT3 BACKGROUND
Since its introduction, Muromonab-CD3 has been successfully used in the treatment of severe AR and as induction therapy in all types of solid organ transplants. OKT3 was found to be useful as an alternative in treating patients who were unresponsive to high corticosteroids and antilymphocyte therapy. A number of centers have used OKT3 induction to spare the newly transplanted patient from the nephrotoxic effects of CSA or high-dose corticosteroids. The use of OKT3 has declined somewht in recent years following the introduction of the IL-2 receptor antibodies because their sideeffect profiles are more favorable.
CHEMISTRY
Muromonab-CD3 (OKT3), a murine monoclonal antibody preparation, causes depletion of circulating T lymphocytes and binds CD3 receptor complex located on T cells. As a result, T cells are rendered immunologically incompetent and are unable to respond to foreign antigen stimuli. OKT3 depletes virtually all circulating T cells within minutes to hours immediately following intravenous administration. Throughout the course of OKT3 therapy, CD3 positive cells will remain depleted while T cells bearing CD2, CD4, and CD8 surface markers reappear. However, shortly following discontinuation of the agent (ϳ48 hours), T cells bearing CD3 as well as other surface markers begin to reappear. Therefore, maintenance immunosuppressants are required to be therapeutic prior to discontinuation of the agent.
PHARMACOKINETICS
Failure to decrease to CD3-positive cells may be suggestive of the production of human antimurine antibodies, which negate OKT3's action. 150 This may be more apparent in patients receiving a second course of therapy and may be monitored by measurement of CD3 cells. Additionally, some patients may exhibit an abnormally increased clearance rate of murine immunoglobulin, resulting in potential therapeutic failures. Patients receiving concomitant immunosuppressants typically have a lower incidence of murine antibody production. 151 
DOSING
The usual dose of OKT3 is 5 mg/day administered for 10 to 14 days, depending on the indication for its use. A number of centers have used alternative regimens including the administration of shorter courses (e.g., three doses) or lower doses (1-2.5 mg/dose) while monitoring CD3 levels to insure adequate therapy.
ADVERSE EFFECTS
OKT3 is associated with many significant adverse drug reactions. The most significant side effects typically occur following the administration of the initial dose of therapy or following an increase in dose. These side effects are largely due to cytokine release syndrome, which results in increased IL-1, IL-6, and tumor necrosis factor from OKT3-activated T cells and monocytes. 152 Some patients have experienced flulike symptoms including fever, chills, headache, nausea, vomiting, diarrhea, and myalgias. However, less frequently some patients have developed pulmonary edema, hypotension, seizures, encephalopathy, renal dysfunction, or aseptic meningitis. Premedication with steroids, acetaminophen, and diphenhydramine is administered approximately 1 hour prior to OKT3 administration to reduce clinical symptoms associated with cytokine release syndrome. 153 OKT3 use has also been associated with rare instances of coagulopathies manifested by thrombocytopenia, or graft thrombosis.
As with all potent immunosuppressants, patients may also be at higher risk of infections or lymphomas.
The development of infection, most commonly manifested as CMV, is likely but also dependent on the overall amount of immunosuppression the patient receives. It is important that high-risk patients receive the appropriate antiviral prophylaxis therapy with ganciclovir while receiving OKT3 or any potent immunosuppressive regimen. As with any immunosuppressive agent, OKT3 has been associated with an increased risk for the development of lymphoma, 154 which is most likely re- lated to the overall level of immunosuppression rather than due to one individual agent.
Antithymocyte Globulins
BACKGROUND
Atgam is a polyclonal antilymphocyte globulin solution that has been available for the past 2 decades. Thymoglobulin is a recently approved polyclonal antithymocyte agent that has been used extensively in Europe.
The major difference between the two products is that Atgam is produced from horses whereas Thymoglobulin is derived from rabbits.
CHEMISTRY
These agents are prepared by inoculating animals (e.g., horses, rabbits, goats) with human thymocytes. The resulting gamma globulin solution is then purified to remove unnecessary materials yielding a solution specific for lymphocytes. Following administration of these agents, their immunosuppressive action is manifested by a profound depletion of peripheral blood lymphocytes. 71 Their immunosuppressive effects are thought to be mediated through several mechanisms: cells coated with antibodies undergo complement mediated cell lysis of lymphocytes or clearance by the reticuloendothelial system. 71 T lymphocyte proliferation may also be affected by the agents.
PHARMACOKINETICS
Atgam and Thymoglobulin have extended half-lives of ϳ5.7 days and 30 days, respectively. However, there have been large variations reported between patients.
DOSING
The recommended dose for Atgam is ϳ10 to 20mg/kg/day for up to 14 days. The first dose should be administered over a 6-hour infusion; subsequent doses may be administered over 4 hours thereafter. The initial dose of Thymoglobulin is also administered over a 6-hour infusion with remaining doses given over a minimum of 4 hours. Because of potency differences, the recommended dose for Thymoglobulin (1.5 mg/kg/day) is approximately one-tenth that of Atgam. A number of centers have modified their protocols to use either lower doses (e.g., 1.0 mg/kg/day) or alternate-day therapy (e.g., 1.5 mg/kg/day qod for a total of four doses over 7 days) rather than wait to adjust the dose because of leukopenia and thrombocytopenia. Both agents may be given for up to 14 days of therapy, but, as already mentioned, many centers are administering much shorter courses of therapy. It is recommended that premedications, including acetaminophen, diphenhydramine, and methylprednisolone, be given within 1 hour prior to administration to ameliorate side effects.
ADVERSE EFFECTS
Common side effects associated with Atgam include leukopenia (29%), fever (63%), chills (43%), nausea (28%), diarrhea (32%), arthralgias, and headache. Anaphylactic-type reactions have rarely occurred with these agents. Both agents are associated with leukopenia and thrombocytopenia, which may require dosage adjustment and/or discontinuation of the agent. However, Thymoglobulin has been associated with an increased incidence of leukopenia at ϳ57%. Patients should be monitored daily while on therapy. Dosages should be decreased by ϳ50% if WBC decreasec less than 3,000 cells/mL or if platelets fall between 50,000 and 100,000 cells/mL. Doses should be held if WBC drops below 2,000 cells/mL or platelets fall below 50,000 cells/mL. These agents are also associated with increased risk of malignancy as well as opportunistic infection-bacterial, viral, and fungal. Appropriate anti-infective prophylaxis therapy is warranted during treatment with these agents. A number of lung transplant centers have used the antilymphocyte therapy for induction, but this remains controversial. 155 Steroids initially were contraindicated immediately following transplantation because of concerns that they could impair anastomotic healing, induction agents were used to augment immunosuppression during that time period. Alterations in surgical technique have eliminated this concern, and many centers no longer use induction therapy. However, the ongoing multicenter trial evaluating the safety and efficacy of MMF compared with an AZA-based regimen includes a standard course of antithymocyte globulin for up to 10 days. 12 Proponents of using induction agents suggest a longer latency period to the development of OB. 156 These agents are used routinely for the treatment of steroid-resistant rejection 157 or to stablilize or delay the progression of OB. 158, 159 These studies are limited by their nonrandomized, single-center design, and more important, by the lack of long-term follow-up (usually only 3 to 6 months) evaluating the success of arresting the progression of OB. Although the data are very limited, the short-term favorable response rate associated with augmented immunosuppression with cytolytic agents has led to this approach being the standard of care for OB at most institutions.
IL-2 Receptor Antagonists
BACKGROUND
Basiliximab and daclizumab are the newest monoclonal antibody preparations introduced onto the market. Basiliximab is a chimeric murine-human monoclonal antibody preparation that contains a larger proportion of murine antibody (25%) constituents. 160 Daclizumab is humanized monoclonal antibody containing a smaller percentage (ϳ10%) of murine antibody sequence. 161 The major advantage of these medications is that they contain primarily human antibody components and have improved side-effect profiles and a lower incidence of immunogenicity compared with OKT3. These agents are not indicated for the treatment of AR.
CHEMISTRY
The IL-2 receptor antagonists bind specifically to the alpha-subunit, also known as the Tac subunit, of the interleukin-2 receptor, which is expressed on the surface of activated T lymphocytes. As a result, T lymphocyte proliferation and differentiation are inhibited.
PHARMACOKINETICS
The IL-2 inhibitors yield a prolonged immunosuppressive action, resulting from half-lives exceeding 7 days; basiliximab ϳ13 days; daclizumab ϳ20 to 40 days. 160, 161 The extended half-life allows the agents to be administered over long dosage intervals. Following administration of basiliximab and daclizumab, the alpha-subunit of IL-2 receptors are effectively saturated for ϳ30 days and ϳ120 days, respectively, potentially contributing to their long-lasting immunosuppressive activity. 160, 161 
DRUG INTERACTIONS
The IL-2 inhibitors have been used concomitantly with a number of immunosuppressive agents including CSA, TRL, MMF, and corticosteroids. No significant drug interactions have been identified for either of these agents.
DOSING
The dosing strategy for these two agents differs based on the number of doses administered and the interval between doses. Although initially studied in a regimen that contained up to six doses of basiliximab, the currently approved regimen for basiliximab includes two doses administered intravenously as a single 20 mg daily dose on the day of transplant and on the fourth day posttransplantation. In contrast, the currently approved regimen for daclizumab is based on 1 mg/kg/day administered within 24 hours of transplant surgery followed by equal doses administered every 14 days for five doses. A number of centers have modified their protocols to include two doses of daclizumab and some are administering a slightly larger loading dose, 2 mg/kg for the first of two doses. An ongoing multicenter heart trial requires that the second dose of daclizumab be administered within 7 days of the first dose. More information is needed regarding the optimal dosing strategy for these agents.
ADVERSE EFFECTS
In clinical renal trials, daclizumab and basiliximab exhibited similar side effects to those associated with patients receiving placebo. Both agents exerted a relatively mild side effect profile and did not cause a cytokine release syndrome or manifest significant first dose effects.
However, recently a "Dear Dr. letter" was sent to all health care practitioners advising them of an increased frequency of pulmonary edema and ARDS-like symptoms seen following the first dose of basiliximab. The lower incidence of pulmonary complications compared with OKT3 is a desirable feature for lung transplant patients in the immediate postoperative period.
Although these agents may cause an increased risk of infection and lymphoproliferative disorders, the overall incidence of infection as well as malignancy was similar to that experienced by those patients receiving placebo in the recent clinical trials. 9, 162 
CLINICAL STUDIES
Experience with these agents in lung transplant recipients is limited to a number of abstracts that have showed favorable short-term results with daclizumab. 163, 164 Longer-term follow-up is necessary to determine their role in lung transplantation.
ALTERNATIVE THERAPIES
Inhaled Corticosteroids
Due to the almost inevitable consequence of developing OB, a number of investigators have attempted to identify alternative methods of delivering immunosuppressive agents to lung transplant patients. Inhaled or nebulized corticosteroids (e.g., budesonide and fluticasone) have been administered as adjunctive therapy in patients unresponsive to intravenous or oral corticosteroid therapy. 129, 130, 165 Aerosolized Cyclosporine A number of investigators have evaluated the delivery of immunotherapy directly into the lung by administering CSA in an aerosolized vehicle. Utilization of this route eliminates the variability in absorption, and higher concentrations are achieved in the lung. 166 It is also possible that some of the toxicity that occurs with systemic administration can be avoided via this route; however, this method is not without side effects. Dissolving CSA in 95% ethanol for inhalation has been reported to cause significant patient discomfort. 166 Other adverse events that have been reported include cough, sore throat, wheezing, and transient increase in dyspnea that have been attributed to the irritant effect of aerosol CSA or its diluent, propylene glycol. 167 Aerosolized CSA has been used as rescue therapy in lung transplant recipients with rejection refractory to conventional immunosuppression and to arrest or slow the progression of OB 13, [167] [168] [169] [170] Even though this appears to be an attractive route of drug delivery, the high incidence of patient intolerance limits its widespread use unless improved vehicles are developed.
Methotrexate
Methotrexate has been used as a rescue agent in heart transplant patients with recalcitrant AR 156 and in lung transplant patients for the same indication. 171 It has also been used to stabilize declining lung function in patients with OB, but its use is limited because of concerns of pulmonary toxicity. 172 
Total Lymphoid Irradiation
The evaluation of effectiveness of total lymphoid irradiation and photopheresis is confounded by the fact that these therapies have typically been used as a last resort in patients who have failed all other therapies. Complications such as lymphopenia predispose patients to infection, and the risk is magnified by the overall immunosuppressive load from the cumulative effect of multiple courses of therapy. 16, 173, 174 Photopheresis Photopheresis has been used in a small numbers of patients to treat refractory lung rejection and to arrest the progression of OB. Favorable results including improvement in the clinical and biological status of patients have been reported; however, follow-up duration has been limited. [175] [176] [177] [178] 
CONCLUSIONS
Better immunosuppressive strategies are needed for lung transplantation. Most centers use regimens consisting of CSA or TRL, AZA or MMF, and prednisone, and some also use induction therapy with the cytolytic agents or the newer IL-2 receptor antagonists. An AR episode may result in a change of therapy (e.g., CSA to TRL, AZA to mycophenolate). When OB or BOS is diagnosed, augmented immunosuppression consisting of methylprednisolone pulses or cytolytic therapy is typically initiated. 158, 159, 179 Changes in maintenance therapy may be implemented in an attempt to slow the progression of the disease. Examples include increasing the maintenance corticosteroid regimen and substituting TRL for CSA, 94, 158 substituting MMF for AZA, 126, [129] [130] [131] or making both substitutions. Other strategies include the addition of methotrexate to the standard triple regimen 172 : photophereis, 173 TLI, 174 and inhaled CSA. 167 Overall, the small number of patients studied, the lack of adequate control groups, and the relatively short follow-up periods have made it difficult to define the effectiveness of these treatments.
